News
10 years joining forces against cancer: Viladecans Contra el Cáncer and IDIBELL strengthen an alliance in the service of research and society
Since 2016, the Viladecans Contra el Cáncer Association has contributed more than €264,000 to IDIBELL research projects
Fifty years of Bellvitge data reveal how pneumococcus, antibiotic resistance and meningitis have evolved
A study of 387 patients, published in The Lancet Microbe, shows major differences in outcomes depending on the route of the infection
Patients and researchers join forces to advance DICER1 syndrome research in Europe
The initiative aims to support families, establish a European patient registry, and accelerate research into an extremely rare condition
Researchers identify a key molecule associated with the risk of colorectal cancer in the blood
ACISOGA could serve as a biomarker to improve the early detection and prevention of colorectal cancer
Artificial intelligence identifies signs of aging in blood stem cells through images of the nucleus
An AI capable of distinguishing between young and aging blood stem cells based on images of the cell nucleus has been designed
“Thanks to REMMA Bellvitge’s research, my children will be spared years of fear and invasive tests” (Maira, patient with Familial Adenomatous Polyposis)
Identifying the exact cause of a rare inherited disease can change the future of entire generations
A genetic discovery at Bellvitge enables a family to anticipate hereditary cancer after years without answers
New genetic research strategies increase the ability to identify underlying genetic cause of rare syndromes
The IDIBELL-HUB-ICO Biobank brings its services and resources to the research community of the Bellvitge Health Campus
More than 40 researchers visited the Biobank yesterday on its first open day
Epigenetic modification could open a new avenue to combat acute myeloid leukaemia
An IDIBELL study shows that increasing the methylation of a histone reduces the proliferation capacity of leukaemia cells